Holen Sie sich die Stockscreener-App
2.79
0.36%
0.01
Handel nachbörslich:
2.84
0.05
+1.79%
Schlusskurs vom Vortag:
$2.78
Offen:
$2.81
24-Stunden-Volumen:
295.23K
Relative Volume:
0.39
Marktkapitalisierung:
$208.69M
Einnahmen:
$405.47M
Nettoeinkommen (Verlust:
$53.66M
KGV:
3.875
EPS:
0.72
Netto-Cashflow:
$131.28M
1W Leistung:
-10.58%
1M Leistung:
-10.00%
6M Leistung:
-26.96%
1J Leistung:
-33.89%
1-Tages-Spanne:
$2.76
$2.8498
1-Wochen-Bereich:
$2.66
$3.195
52-Wochen-Spanne:
$2.36
$4.61
Orasure Technologies Inc Stock (OSUR) Company Profile
Firmenname
Orasure Technologies Inc
Sektor
Telefon
(503) 641-6115
Adresse
220 E FIRST ST, BETHLEHEM, PA
Vergleichen Sie OSUR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OSUR
Orasure Technologies Inc
|
2.79 | 208.81M | 405.47M | 53.66M | 131.28M | 0.72 |
|
ISRG
Intuitive Surgical Inc
|
471.85 | 168.51B | 9.15B | 2.61B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
192.50 | 49.42B | 21.39B | 1.59B | 2.55B | 5.56 |
|
RMD
Resmed Inc
|
284.32 | 41.12B | 5.15B | 1.40B | 1.65B | 9.51 |
|
ALC
Alcon Inc
|
84.68 | 41.61B | 9.93B | 1.12B | 1.58B | 2.25 |
|
WST
West Pharmaceutical Services Inc
|
240.33 | 17.06B | 2.90B | 467.20M | 306.90M | 6.37 |
Orasure Technologies Inc Stock (OSUR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-01-03 | Fortgesetzt | Evercore ISI | In-line |
| 2021-09-22 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-08-21 | Eingeleitet | Evercore ISI | Outperform |
| 2020-08-10 | Eingeleitet | Citigroup | Buy |
| 2020-08-10 | Eingeleitet | JP Morgan | Neutral |
| 2020-08-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-06-25 | Eingeleitet | Lake Street | Buy |
| 2020-04-21 | Fortgesetzt | Stephens | Equal-Weight |
| 2018-10-23 | Fortgesetzt | Raymond James | Mkt Perform |
| 2018-07-16 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2017-11-02 | Herabstufung | Jefferies | Buy → Hold |
| 2017-02-09 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2016-06-13 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2015-11-05 | Bestätigt | Mizuho | Buy |
| 2015-05-07 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-01-23 | Bestätigt | Mizuho | Buy |
| 2014-06-12 | Bestätigt | Canaccord Genuity | Buy |
| 2014-06-11 | Bestätigt | Mizuho | Buy |
| 2012-12-21 | Eingeleitet | Mizuho | Buy |
| 2012-08-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2012-07-05 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2012-03-27 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Orasure Technologies Inc Aktie (OSUR) Neueste Nachrichten
OraSure Technologies Inc. stock prediction for this weekAI-Based Stock Behavior Forecast Engine - Newser
Is this a good reentry point in OraSure Technologies Inc.Free Value Investing Picks With Stability - Newser
Visualizing OraSure Technologies Inc. stock with heatmapsFree Pattern Breakout Entry Stock Forecast - Newser
Risk adjusted return profile for OraSure Technologies Inc. analyzedSwing Trade Picks with High Potential - Newser
OraSure Technologies, Inc. (NASDAQ:OSUR) Analysts Are Pretty Bullish On The Stock After Recent Results - simplywall.st
What momentum shifts mean for OraSure Technologies Inc.Equity Performance Forecast Based on AI Models - Newser
Why OraSure Technologies Inc. stock attracts strong analyst attentionFree Weekly Setup With 3x Return Potential - Newser
OraSure Technologies, Inc. (NASDAQ:OSUR) Q2 2025 Earnings Call Transcript - Insider Monkey
OraSure (OSUR) Q2 Revenue Falls 43% - AOL.com
OraSure Technologies Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Orasure Technologies 2025 Q2 Earnings Deepened Losses Amid Sharp Revenue Drop - AInvest
OraSure Q2 Earnings Call: Revenue Growth, Innovation Progress, and Challenges Ahead - AInvest
OraSure reports second quarter earnings amid 'continued uncertainty' - WFMZ.com
OraSure Technologies Q2 2025 Earnings: Revenue Down 43%, EPS Misses Expectations - AInvest
OraSure Reports Q2 Earnings in Line with Expectations, Raises Novel Blood Collection Device for Proteomic Research - AInvest
OraSure Technologies Q2 Financial Results: $19.7 Million LossNews and Statistics - IndexBox
OraSure Technologies Inc (OSUR) Q2 2025 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance
OraSure signals Q3 revenue outlook of $27M–$30M as it launches new proteomics product and completes manufacturing transition - MSN
OraSure: Q2 Earnings Snapshot - Greenwich Time
OraSure Technologies Reports Q2 2025 Financial Results - TipRanks
OraSure's Strategic Transformation: A High-Conviction Play in the Evolving Diagnostics Sector - AInvest
OraSure's Q2 2025: Unpacking Key Contradictions in Margins, Demand, and Revenue Outlook - AInvest
OraSure Q3 Revenue Outlook Revised to $27M-$30M Amid New Proteomics Product Launch and Manufacturing Transition Completion. - AInvest
OraSure’s Covid Come-Down Triggers Revenue Drop, But Outlook Brightens - Finimize
Transcript : OraSure Technologies, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Earnings call transcript: OraSure Q2 2025 results show mixed performance By Investing.com - Investing.com South Africa
Earnings call transcript: OraSure Q2 2025 results show mixed performance - Investing.com India
OraSure Technologies (OSUR) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
OraSure Technologies Q2 Earnings: -$19.69mln, -$0.26 EPS, $31.24mln Revenue - AInvest
OraSure Technologies Inc reports results for the quarter ended June 30Earnings Summary - TradingView
OraSure Q2 Revenue Down 43% Amidst Appointments and M&A Activity - AInvest
OraSure Q2 revenue falls 43% - MarketScreener
OraSure Technologies Reports 43% Revenue Decline in Q2 2025 - TipRanks
OraSure Announces Second Quarter 2025 Financial Results - GlobeNewswire
RENEW 8-K: Ninth SPAC Extension Adds $250k to Trust, Deadline Sep 5 2025 | OSUR SEC FilingForm 8-K - Stock Titan
OraSure Technologies Inc. Recovery Hinges on Volume BreakoutScalable Portfolio Growth Suggestions Released - beatles.ru
CRISPR-Based Diagnostics Market Driven by Rapid Detection - openPR.com
OraSure Appoints Anne Messing as Chief Commercial Officer - The Manila Times
Wave Life Sciences Ltd. shares rise 6.03% premarket after OraSure Technologies appoints new Chief Commercial Officer. - AInvest
What analysts say about OraSure Technologies Inc. stockInvest smarter with actionable trading signals - Jammu Links News
How volatile is OraSure Technologies Inc. stock compared to the marketAchieve superior returns through strategic trading - Jammu Links News
What makes OraSure Technologies Inc. stock price move sharplyInvest confidently with real-time market updates - Jammu Links News
What institutional investors are buying OraSure Technologies Inc. stockFree Stock Market Query - Jammu Links News
Why OraSure Technologies Inc. is moving todayExpert-Backed High Yield Stock Watchlist - Newser
What is the risk reward ratio of investing in OraSure Technologies Inc. stockUnlock exclusive stock market forecasts - Jammu Links News
How many analysts rate OraSure Technologies Inc. as a “Buy”Extraordinary profit generation - Jammu Links News
OraSure Technologies Inc. Approaches Psychological Resistance LevelPotential Breakout Stock List Published This Week - beatles.ru
OraSure Technologies Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Does OraSure Technologies Inc. stock perform well during market downturnsRetirement Planning Report With Low Risk - Jammu Links News
GSA Capital Partners LLP Has $928,000 Stock Holdings in OraSure Technologies, Inc. (NASDAQ:OSUR) - Defense World
Key resistance and support levels for OraSure Technologies Inc.Growth Focused Entry Plan Suggestions Issued - metal.it
Finanzdaten der Orasure Technologies Inc-Aktie (OSUR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Orasure Technologies Inc-Aktie (OSUR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| EGLINTON MANNER CARRIE | President & CEO |
Feb 28 '25 |
Buy |
3.49 |
28,670 |
100,027 |
1,288,334 |
| EGLINTON MANNER CARRIE | President & CEO |
Feb 27 '25 |
Buy |
3.15 |
78,625 |
247,378 |
1,259,664 |
| Kenny John P. | Director |
Feb 27 '25 |
Buy |
3.17 |
47,659 |
151,217 |
70,915 |
| McGrath Kenneth J | Chief Financial Officer |
Feb 27 '25 |
Buy |
3.15 |
64,000 |
201,683 |
371,013 |
| Marmora Lelio | Director |
Feb 27 '25 |
Buy |
3.06 |
7,000 |
21,420 |
67,720 |
3.62%
0.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):